Hua Medicine Ltd. provides drug discovery and development services. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2018-09-14. The firm is also engaged in the commercialization of HuaTangNing products. The Company’s main product pipeline dorzagliatin or HMS5552 is a glucokinase activator or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The firm mainly conducts its business in the domestic market.
Follow-Up Questions
Hua Medicine のCEOは誰ですか？
Dr. Li Chen は Hua Medicine の Chief Executive Officer で、2010 から在籍しています。
HUMDF の株価パフォーマンスは？
HUMDF の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
Hua Medicine の主な事業テーマや業界は？
Hua Medicine は Pharmaceuticals 業界、セクターは Health Care に属しています。
